

Pre-Admission Blood Pressure and Outcome in a Large Telestroke Cohort

Elias Atallah MD, Kimon Bekelis MD, Nohra Chalouhi MD, Hasan Saad MD, Sophia Dang, Jonathan Li, Ayan Kumar, Justin Turpin, Randa Barsoom, Stavropoula Tjoumakaris MD, David Hasan MD, MD, JL, Robert H. Rosenwasser MD, Pascal Jabbour MD Sidney Kimmel Medical College, Department of Neurosurgery, Thomas Jefferson University Hospital

Introduction

- 55% of Americans live within 60 miles of a primary stroke
- Telestroke (TS) units shorten treatment delivery times (reduce permanent neurologic sequelae.^{1,2}
- TS units provide tele-consults with neurovascular specialists experienced in medical and surgical treatment of acute ischemic stroke (AIS).
- Maintenance of systolic blood pressure (SBP) > 140mmHg is recommended in AIS management.
- SBP < 140mmHg is independently predictive of poor neurologic outcome.³
- We analyzed all patients with AIS symptoms transported to Thomas Jefferson University Hospital (TJUH), via JeffSTAT EMS ground vehicles or helicopters, to verify efficiency of the TS system and the prognostic value of vital sign-monitoring throughout the transportation process.

Study Design

- <u>Cohort</u>:
 - -AIS patients presenting to Telestroke (TS) hospital network of over 40 regional medical institutions within PA and NJ from 2011-2016 (n=2,928).
- Data points:
 - -HRR*, BP, MAP* were collected: (1) at presentation to TS unit, (2) during transportation and (3) at arrival to TJUH
 - -NIHSS was collected: (1) at presentation to TS unit, (2) at arrival to TJUH
 - -DTN*, IV rt-PA status, CTA-CTP*, MT* status, TICI*
- Outcome Variables:
 - 1. Influence of SBP variations during transportation on clinical outcome, measured by modified Rankin Score (mRS) on discharge, latest follow-up, and mortality rate.
 - 2. Number of patients who received MT and/or rt-PA.
- Covariates and Comorbidities (risk-adjusted):
 - -Age and gender
 - -Risk factors of hypertension (HTN), diabetes mellitus (DM), and smoking
 - -Hospital course: MT, TICI score, recanalization device, IV rt-PA, NIHSS pre-treatment.
- Statistical Analysis:
 - -Regression diagnostics were performed for all analyses. -Study sample of 1,354 patients \rightarrow 80% power to detect a difference in mortality as small as 7.6%, at an α -level of 0.05.
 - -All probability values were the result of two-sided tests.
 - -Stata version 13 (StataCorp, College Station, TX) was used for statistical analysis.

*Abbrev: heart rate & rhythm (HRR), mean arterial pressure (MAP), door-to-needle time (DTN), Computed Tomography Angiography-Perfusion (CTA-CTP), mechanical thrombectomy (MT), Thrombolysis in Cerebral Infarction (TICI) scale

cent	er.	
e.g.	rt-PA)	and

Outcomes										
Gender			n		%					
Female	644			47.	6					
Male		709			52.	4				
Total		1353			10	D				
		Μ	ean		SE)	Min		Max	
Age		66.6			15.4				111	
NIHSS pre-interv	vention	8.67			8.38		0		38	
Treatment		n			%					
Standard medica	al protocol	7	'17		53.					
IV rt-PA	-	5	95		23.	7				
IV rt-PA & Me	edical	2	73		46)				
MT		(93		3.4	1				
MT & IV rt-PA	A	2	46		49					
IV rt-PA (no MT))	M	ean		SE		Min		Max	
pre-treatment NI	HSS	8	8.37		8.3		0		38	
DTN (min)		Ç	96		46.	46.0			200	
outcome mRS (6	60.7% < 2)	2.11			2.02					
Mortality rate		C	0.1		0.4					
MT (includes rt-PA)		Mean SD)	Min		Max			
pre-treatment NIHSS		12.8			7.88		0		32	
TICI score		2.99		1.6		0		3		
outcome mRS (37.6% < 2)		2.9		1.66						
Mortality rate		0.17 0.97								
	Before tr	ansportat	ion	Dur	ring trar	nsportatior	Afte	er trans	ansportation	
	Mean	SD		Mean		SD	M	ean	SD	
MAP (mmHg)	103.4	16.5	51	10)3.02	18.36	10)1.3	17.37	
SBP	148.39	25.3	89	14	8.51	26.5	14	45.3	24.36	
		mR	S				Mor	tality		
	OR	CI 95	5%	p-\	value	OR	CI	95%	p-value	
SBP ₁	0.007	0.004-0	0.003	С).71	0.99	0.98	8-1.01	0.41	
MAP ₁	0.002	0.01-0	.004	0.56 0.9		0.98	0.97	7-1.00	0.09	
SBP ₂	0.000	0.004-0.003		0.84 0.99		0.99	0.98	8-1.00	0.24	
MAP ₂	0.000	0.01-0.005		0.89 0.99		0.98	8-1.01	0.28		
SBP ₃	0.000	0.002-0.004		0.61 0.99		0.98	8-1.01	0.61		
MAP ₃	0.002	0.0051-0.0053		С	0.96 0.99		0.98	3-1.00	0.18	
		< 140 mmHg			140-	185 mmH	g	> 185 mmHg		
SDF uuring tra		Mean	SD		Mean	SD	M	ean	SD	
pre-interventior	NIHSS	8.41	8.65	5	8.53	8.40	8	.41	7.03	
Treated with IV	rt-PA	22	.3%				16.4%			
Treated with MT		8.	1%			5.7%		1.8%		

Outcomes											
Gender			n		%						
Female	644			47 6							
Male	709			52.	4						
Total	1353			10	0						
		R.A.	000		95	•		Min	Max		
Ago					J 5) Л		16	111		
Aye	vontion	8.67			15.4			0	20		
MINOS pre-inter	Vention	0	.07		0.0	0		0	30		
Treatment		n			%						
Standard medica	al protocol	7	17		53.	0					
IV rt-PA		5	595		23.7						
IV rt-PA & Me	edical	2	273		46	6					
MT			93		3.4	1					
MT & IV rt-PA	4		46		49						
IV rt-PA (no MT)	Mean			SD			Min	Max		
pre-treatment NIHSS		8.37			8.3			0	38		
DTN (min)	TN (min)		96		46.0			0	200		
outcome mRS (60.7% < 2)		2.11		2.02							
Mortality rate		0.1		0.4							
MT (includes rt	-PA)	Μ	ean		SE)		Min	Max		
pre-treatment N	IHSS	12.8		7.88			0	32			
TICI score		2.99		1.6			0	3			
outcome mRS (37.6% < 2)		2.9		1.66							
Mortality rate		0.17			0.97						
Before tra		ansportation		During transportation			ation	After transportation			
	Mean	SD		Mean		SD		Mean	SD		
MAP (mmHg)	103.4	16.5	51	10)3.02	18	.36	101.3	17.37		
SBP	148.39	25.3	39	14	18.51	26	6.5	145.3	24.36		
		mR	S					Mortality			
	OR	CI 95	5%	p-\	value	С	R	CI 95%	p-value		
SBP ₁	0.007	0.004-0	0.003	<u> </u>).71	0.	99	0.98-1.01	0.41		
MAP ₁	0.002	0.01-0	.004	0.56 0.9		98	0.97-1.00	0.09			
SBP ₂	0.000	0.004-0.003		0.84 0.99		99	0.98-1.00	0.24			
MAP_2	0.000	0.01-0.005		С	0.89 0.99		99	0.98-1.01	0.28		
SBP ₃	0.000	0.002-0.004		С	0.61 0.99		99	0.98-1.01	0.61		
MAP ₃	0.002	0.0051-0.0053 (C	0.96 0.99		99	0.98-1.00	0.18		
		< 140 mmHa			140-185 mmHa			> 185 mmHa			
SBP during tra	ansport	Mean	lean SD		Mean SD		SD	Mean	SD		
pre-interventior	n NIHSS	8.41	8.65		8.53		8.40	8.41	7.03		
Treated with IV	′ rt-PA	22	.3%		22.0%			16	16.4%		
Treated with M	т	8.	1%			5.7%)	1.8	1.8%		

59.0%

.29

CI 95%

-0.38-0.96

(p=0.397)

0.52-1.55

(p=0.705)

54.5%

CI 95%

-0.39-0.97

(p=0.410)

0.61-1.58

(p=0.945)

OR

0.28

0.98

CDD during transport	< 14	140-	
SBP during transport	Mean	SD	Mean
pre-intervention NIHSS	8.41	8.65	8.53
Treated with IV rt-PA	2	2.3%	
Treated with MT	8	3.1%	
Outcome mRS < 2	6		
Correlations	OR	CI 95%	OR
Latest mRS	1.167	-0.04-0.96 (p=0.422)	0.29
Mortality	1.167	0.21-6.38 (p=0.858)	0.89

- treatment.

- min.
- 2).
- REACH), and other European TS studies.

Limitations:

- BP.⁴
- and are extrapolated from cardiac literature.
 - clinical outcome.

current international TS studies.

- findings.

Dr. Elias Atallah for the opportunity to be a part of his research team, the team members, and the Department of Neurosurgery at Thomas Jefferson University.

- TS service. Neurosurgery. 2013;73(4):667-671; discussion 671-662.

- stroke outcome. Neurology. 2006;66(12):1878-1881.
- 1994;344(8916):156-159.

Discussion

• Patients who received MT had higher NIHSS on admission, prior to

• Patients with SBP > 185 mmHg during transportation were least likely to receive IV rt-PA, MT, and had less good clinical outcomes (mRS \leq 2).

- However, reasons for exclusion from IV rt-PA treatment is not entirely known due to retrospective nature of study.

• Efficient TS network protocol increases the number of stroke patients treated and yields better outcomes by decreasing DTN.

– Less than $\frac{1}{3}$ of patients (27.3%) received IV rt-PA within DTN ≤ 60

- 55.63% (153/275) of patients treated with IV rt-PA, via TS consultation, had a good clinical outcome on latest follow-up (mRS \leq

- These results are better than previously published (TEMPiS and

• Study design is limited by its retrospective nature. • We did not consider pre-existing HTN; we could have collected relative

• Though studies report high BP and increases in BP to be associated with worse outcomes, there is no data supporting causation.⁵⁻⁷

• Cutoff limit of SBP values used in management of stroke lack evidence

-More randomized clinical trials are needed to elucidate the relationship between SBP during acute phase of ischemic stroke and

Conclusion

• TS service enables rapid assessment and reduced DTN. This study displayed better clinical outcomes at latest follow-up when compared to

• SBP was not associated with higher mortality and morbidity.

• Future studies should address limitations of this study to confirm these

Acknowledgements

Bibliography

Chalouhi N, Dressler JA, Kunkel ES, et al. Intravenous tissue plasminogen activator administration in community hospitals facilitated by 2. Akbik F, Hirsch JA, Chandra RV, et al. TS-the promise and the challenge. Part one: growth and current practice. J Neurointerv Surg.

3. Bowry R, Navalkele DD, Gonzales NR. Blood pressure management in stroke: Five new things. *Neurol Clin Pract.* 2014;4(5):419-426. 4. McManus M, Liebeskind DS. Blood Pressure in Acute Ischemic Stroke. *J Clin Neurol.* 2016;12(2):137-146. 5. Stead LG, Gilmore RM, Vedula KC, Weaver AL, Decker WW, Brown RD, Jr. Impact of acute blood pressure variability on ischemic

6. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Effect of blood pressure and diabetes on stroke in progression. Lancet.

7. Ntaios G, Lambrou D, Michel P. Blood pressure change and outcome in acute ischemic stroke: the impact of baseline values, previous hypertensive disease and previous antihypertensive treatment. *J Hypertens.* 2011;29(8):1583-1589.